These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6161279)

  • 1. Effect of actinomycin D-containing lipid vesicles on murine renal adenocarcinoma.
    Kedar A; Mayhew E; Moore RH; Williams P; Murphy GP
    J Surg Oncol; 1980; 15(4):363-5. PubMed ID: 6161279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of actinomycin D entrapped in liposomes to prolong survival in renal cell adenocarcinoma-bearing mice.
    Kedar A; Mayhew EG; Moore RH; Murphy GP
    Oncology; 1981; 38(5):311-4. PubMed ID: 7266972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody.
    Hashimoto Y; Sugawara M; Masuko T; Hojo H
    Cancer Res; 1983 Nov; 43(11):5328-34. PubMed ID: 6616468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362.
    Dinney CP; Bucana CD; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ
    Cancer Res; 1991 Jul; 51(14):3741-7. PubMed ID: 1905975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of tumour bearing mice with liponsome-entrapped actinomycin D prolongs their survival.
    Gregoriadis G; Neerunjun ED
    Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):351-62. PubMed ID: 1153840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.
    Dinney CP; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ
    Cancer Res; 1992 Mar; 52(5):1155-61. PubMed ID: 1531322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of chrysin on steroid-resistant asthma in a murine model].
    Yao J; Du Q; Feng G
    Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(24):1957-60. PubMed ID: 26710703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of Methyl-GAG on a transplantable murine renal cell adenocarcinoma.
    Williams PD; Murphy GP
    Res Commun Chem Pathol Pharmacol; 1983 Jan; 39(1):153-61. PubMed ID: 6844733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells.
    Papahadjopoulos D; Poste G; Vail WJ; Biedler JL
    Cancer Res; 1976 Sep; 36(9 pt.1):2988-94. PubMed ID: 975068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A report of an actinomycin D study group in Japan.
    Takatsu T
    Paediatr Univ Tokyo; 1970 Jan; 17():7-9. PubMed ID: 4315852
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor.
    Wolff JA; D'Angio G; Hartmann J; Krivit W; Newton WA
    N Engl J Med; 1974 Jan; 290(2):84-6. PubMed ID: 4357042
    [No Abstract]   [Full Text] [Related]  

  • 12. Late treatment of murine lupus erythematosus with dactinomycin (actinomycin D). I. Course and longevity.
    Gabrielsen AE; Olsen CT
    Clin Exp Immunol; 1979 Jan; 35(1):33-5. PubMed ID: 428145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soft agar colony formation assay for in vitro chemotherapy sensitivity testing of human renal cell carcinoma: Mayo Clinic experience.
    Lieber MM
    J Urol; 1984 Feb; 131(2):391-3. PubMed ID: 6199522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results.
    Lasek W; Giermasz A; Kuc K; Wańkowicz A; Feleszko W; Gołab J; Zagozdzon R; Stokłosa T; Jakóbisiak M
    Int J Cancer; 1996 May; 66(3):374-9. PubMed ID: 8621260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actinomycin D for Wilm's tumour.
    Rickham PP
    Br Med J; 1973 Apr; 2(5858):114. PubMed ID: 4349464
    [No Abstract]   [Full Text] [Related]  

  • 16. Liposome-cell interactions. A study of the interactions of liposomes containing entrapped anti-cancer drugs with the EMT6, S49 and AE1 (transport-deficient) cell lines.
    Allen TM; McAllister L; Mausolf S; Gyorffy E
    Biochim Biophys Acta; 1981 May; 643(2):346-62. PubMed ID: 7225387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of intravascular metastases of B16 murine melanoma: adjuvant chemotherapy with actinomycin D.
    Richie JP
    J Surg Oncol; 1982 Jul; 20(3):145-50. PubMed ID: 7087484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of the Wilms' tumor with actinomycin D.
    Sipahi ML
    Turk J Pediatr; 1969 Jul; 11(3):98-105. PubMed ID: 4313305
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours.
    Kaye SB; Boden JA; Ryman BE
    Eur J Cancer (1965); 1981 Mar; 17(3):279-89. PubMed ID: 6943028
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.